Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. VGNT
VGNT logo

VGNT Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Versigent PLC (VGNT) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Buy
Latest Price
34.700
1 Day change
6.41%
52 Week Range
--
Analysis Updated At
2026/04/17
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Versigent PLC (VGNT) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock is undervalued post-spinout, has strong analyst support with price targets significantly above the current price, and shows promising financial growth trends. Despite some risks in guidance and gross margin decline, the long-term growth potential outweighs these concerns.

Technical Analysis

No stock trend data available for technical analysis. The pre-market price is $32.8, up 0.58%, indicating slight positive sentiment.

Positive Catalysts

  • Multiple analysts initiated coverage with Buy ratings and price targets ranging from $35 to $47, citing undervaluation and strong growth potential.

  • UBS highlights potential buyback authorization or dividend initiation as positive catalysts.

  • Revenue and net income growth in the latest quarter are strong, with net income up 70.87% YoY.

Neutral/Negative Catalysts

  • Gross margin dropped by 9.85% YoY, which could indicate cost pressures.

  • Some analysts acknowledge risks around guidance and software-defined vehicles, though they do not view these as lasting overhangs.

Financial Performance

In Q4 2025, revenue increased by 8.18% YoY to $2.302 billion. Net income surged by 70.87% YoY to $217 million, and EPS rose by 70.39% YoY to $3.05. However, gross margin declined to 11.9%, down 9.85% YoY.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts are overwhelmingly positive, with Buy ratings from TD Cowen ($47 target), UBS ($43 target), Fox Advisors ($35 target), and Wells Fargo ($35 target). They highlight undervaluation, strong growth potential, and possible shareholder returns as key drivers.

Wall Street analysts forecast VGNT stock price to rise
0 Analyst Rating
0
Wall Street analysts forecast VGNT stock price to rise
0 Buy
0 Hold
0 Sell
0
Current: 32.610
sliders
Low
0
Averages
0
High
0
0
Current: 32.610
sliders
Low
0
Averages
0
High
0
TD Cowen
Buy
initiated
$47
AI Analysis
2026-04-14
Reason
TD Cowen
Price Target
$47
AI Analysis
2026-04-14
initiated
Buy
Reason
TD Cowen initiated coverage of Versigent (VGNT) with a Buy rating and $47 price target. The recent spin from Aptiv (APTV) has left the shares undervalued relative to the quality of the business, argues the analyst, who acknowledges some "legitimate debates" around guidance risk and software-defined vehicles, but doesn't view them as "lasting overhangs."
UBS
NULL
to
Buy
initiated
$43
2026-04-14
Reason
UBS
Price Target
$43
2026-04-14
initiated
NULL
to
Buy
Reason
UBS initiated coverage of Versigent with a Buy rating and $43 price target. The firm views the stock's valuation multiple as "too dire." It sees the shares re-rating "as long as management commits to a consistent capital return program." A potential buyback authorization and/or dividend initiation are likely positive catalysts for Versigent, the analyst tells investors in a research note.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for VGNT
Unlock Now

People Also Watch